Hosted on MSN1mon
Trinity Biotech announces breakthrough in CGM technology
John Gillard, CEO of Trinity Biotech, emphasized that their patented technology is set to disrupt the CGM market, which is expected to surpass $20 billion by 2029. He highlighted the ergonomic ...
Drug Delivery Business4d
Trinity Biotech to undergo strategic realignment, focus on CGM development
Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.
Nasdaq4d
Trinity Biotech Appoints Barclays Capital as Exclusive Financial Advisor to Advance Continuous Glucose Monitoring Technology Transformation Plan
Trinity Biotech plc announced a significant step in its transformation plan by appointing Barclays Capital Inc. as its exclusive financial advisor. The company is shifting its focus to developing ...
HME News4d
Trinity Biotech zeroes in on CGM
Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...